Skip to Main Content
Table 3—

Frequencies and age-adjusted ORs (95% CI) for the metabolic syndrome abnormalities and the metabolic syndrome according to standardized values of log(ferritin) and transferrin, at entry* and at 6 years follow-up: DESIR

% with abnormalities
Log(ferritin)
Transferrin
Inclusion6 yearsInclusion6 yearsInclusion6 years
Men (n = 469)       
    Abdominal obesity 32 39 1.48 (1.18–1.85) 1.44 (1.11–1.87) 1.62 (1.31–1.99) 1.14 (0.89–1.46) 
    High blood pressure 67 70 1.14 (0.94–1.39) 1.38 (1.10–1.73) 1.08 (0.88–1.32) 1.43 (1.12–1.81) 
    Hypo-HDL cholesterolemia 14 20 1.53 (1.12–2.08) 1.22 (0.91–1.63) 1.72 (1.31–2.25) 1.48 (1.13–1.94) 
    Hypertriglyceridemia 24 31 1.47 (1.15–1.88) 1.35 (1.06–1.71) 2.04 (1.62–2.58) 1.50 (1.19–1.89) 
    Hyperglycemia 48 44 1.24 (1.02–1.50) 1.21 (0.99–1.48) 1.02 (0.84–1.22) 1.33 (1.09–1.63) 
    Metabolic syndrome       
IDF 21 28 1.49 (1.14–1.94) 1.46 (1.13–1.89) 1.94 (1.53–2.47) 1.41 (1.10–1.81) 
NCEP original 7.3 9.0 2.16 (1.34–3.49) 1.73 (1.13–2.64) 1.09 (0.77–1.55) 1.48 (1.07–2.08) 
NCEP revised 20 28 1.62 (1.22–2.14) 1.42 (1.09–1.84) 1.78 (1.39–2.27) 1.54 (1.20–1.97) 
    Hyperinsulinemia 25 33 1.66 (1.30–2.13) 1.34 (1.06–1.69) 1.52 (1.22–1.88) 1.48 (1.19–1.85) 
    High HOMA-IR 25 32 1.69 (1.31–2.18) 1.34 (1.06–1.69) 1.58 (1.27–1.96) 1.47 (1.08–1.84) 
    Low HOMA-%β 25 32 1.35 (1.07–1.70) 1.10 (0.88–1.38) 1.46 (1.18–1.81) 1.32 (1.06–1.65) 
Premenopausal women (n = 278)       
    Abdominal obesity 25 39 1.54 (1.13–2.09) 1.82 (1.29–2.56) 1.79 (1.30–2.46) 1.50 (1.06–2.14) 
    High blood pressure 34 36 1.28 (0.96–1.69) 1.12 (0.82–1.54) 1.25 (0.94–1.66) 1.33 (0.98–1.82) 
    Hypo-HDL cholesterolemia 14 1.81 (1.17–2.80) 0.99 (0.67–1.47) 1.59 (1.03–2.46) 1.35 (0.93–1.96) 
    Hypertriglyceridemia 10 14 1.99 (1.29–3.07) 1.24 (0.83–1.86) 2.50 (1.61–3.88) 1.24 (0.82–1.87) 
    Hyperglycemia 17 16 1.58 (1.13–2.21) 1.23 (0.84–1.80) 0.89 (0.62–1.28) 1.41 (0.96–2.08) 
    Metabolic syndrome       
IDF 7.9 15 2.10 (1.27–3.48) 1.28 (0.85–1.94) 2.22 (1.32–3.75) 1.63 (1.05–2.52) 
NCEP original 4.0 4.7 1.72 (0.89–3.35) 1.26 (0.65–2.45) 2.88 (1.50–5.51) 0.76 (0.39–1.45) 
NCEP revised 6.5 11 2.27 (1.26–4.09) 1.66 (1.03–2.68) 3.36 (1.78–6.32) 1.19 (0.71–1.99) 
    Hyperinsulinemia 25 30 1.70 (1.26–2.20) 1.22 (0.90–1.65) 1.62 (1.20–2.19) 1.58 (1.16–2.15) 
    High HOMA-IR 25 29 1.74 (1.28–2.35) 1.30 (0.95–1.78) 1.58 (1.17–2.15) 1.56 (1.14–2.14) 
    Low HOMA-%β 25 32 1.42 (1.05–1.93) 1.26 (0.93–1.71) 2.00 (1.47–2.73) 1.39 (1.02–1.88) 
Postmenopausal women (n = 197)       
    Abdominal obesity 46 58 1.55 (1.13–2.11) 1.12 (0.79–1.59) 1.53 (1.12–2.08) 1.15 (0.80–1.65) 
    High blood pressure 64 71 1.12 (0.82–1.53) 1.41 (0.98–2.04) 0.87 (0.64–1.19) 0.72 (0.51–1.02) 
    Hypo-HDL cholesterolemia 18 31 1.86 (1.20–2.89) 1.28 (0.87–1.88) 2.32 (1.55–3.47) 1.31 (0.89–1.94) 
    Hypertriglyceridemia 18 33 1.61 (1.04–2.49) 2.19 (1.46–3.27) 2.74 (1.79–4.20) 1.24 (0.84–1.84) 
    Hyperglycemia 24 23 1.45 (1.02–2.06) 1.43 (0.97–2.11) 1.32 (0.95–1.83) 1.32 (0.93–1.88) 
    Metabolic syndrome       
IDF 24 35 1.80 (1.21–2.68) 1.62 (1.10–2.38) 2.14 (1.47–3.10) 1.51 (1.02–2.22) 
NCEP original 8.6 12 1.74 (0.96–2.72) 1.77 (1.00–3.13) 1.37 (0.84–2.23) 1.20 (0.74–1.93) 
NCEP revised 21 34 1.88 (1.22–2.88) 1.62 (1.08–2.43) 2.10 (1.42–3.09) 1.07 (0.71–1.61) 
    Hyperinsulinemia 26 34 2.23 (1.52–3.27) 1.34 (0.93–1.92) 1.20 (0.86–1.67) 1.22 (0.87–1.71) 
    High HOMA-IR 25 32 2.16 (1.46–3.17) 1.30 (0.90–1.87) 1.19 (0.85–1.66) 1.26 (0.89–1.77) 
    Low HOMA-%β 25 34 1.37 (0.97–1.94) 1.16 (0.83–1.62) 1.04 (0.75–1.44) 1.23 (0.89–1.70) 
All individuals (n = 944)       
    Abdominal obesity 33 43 1.52 (1.30–1.77) 1.44 (1.21–1.72) 1.62 (1.39–1.88) 1.20 (1.01–1.43) 
    High blood pressure 57 60 1.19 (1.03–1.36) 1.30 (1.11–1.53) 1.06 (0.92–1.22) 1.22 (1.04–1.44) 
    Hypo-HDL cholesterolemia 13 20 1.67 (1.34–2.07) 1.17 (0.97–1.43) 1.82 (1.50–2.21) 1.42 (1.18–1.72) 
    Hypertriglyceridemia 19 26 1.60 (1.32–1.94) 1.50 (1.25–1.79) 2.24 (1.86–2.69) 1.39 (1.17–1.66) 
    Hyperglycemia 34 31 1.36 (1.17–1.58) 1.27 (1.08–1.49) 1.03 (0.89–1.19) 1.34 (1.14–1.57) 
    Metabolic syndrome       
IDF 18 26 1.70 (1.39–2.08) 1.47 (1.22–1.78) 2.01 (1.67–2.43) 1.46 (1.22–1.76) 
NCEP original 6.6 8.4 1.85 (1.37–2.51) 1.70 (1.27–2.28) 1.37 (1.07–1.77) 1.27 (1.00–1.63) 
NCEP revised 16 25 1.78 (1.43–2.20) 1.52 (1.25–1.85) 1.99 (1.63–2.42) 1.37 (1.13–1.66) 
    Hyperinsulinemia 25 32 1.78 (1.50–2.10) 1.30 (1.10–1.53) 1.46 (1.26–1.70) 1.46 (1.25–1.71) 
    High HOMA-IR 25 31 1.80 (1.52–2.14) 1.32 (1.11–1.56) 1.48 (1.27–1.73) 1.45 (1.23–1.70) 
    Low HOMA-%β 25 32 1.34 (1.14–1.57) 1.14 (0.97–1.34) 1.48 (1.27–1.73) 1.32 (1.13–1.54) 
% with abnormalities
Log(ferritin)
Transferrin
Inclusion6 yearsInclusion6 yearsInclusion6 years
Men (n = 469)       
    Abdominal obesity 32 39 1.48 (1.18–1.85) 1.44 (1.11–1.87) 1.62 (1.31–1.99) 1.14 (0.89–1.46) 
    High blood pressure 67 70 1.14 (0.94–1.39) 1.38 (1.10–1.73) 1.08 (0.88–1.32) 1.43 (1.12–1.81) 
    Hypo-HDL cholesterolemia 14 20 1.53 (1.12–2.08) 1.22 (0.91–1.63) 1.72 (1.31–2.25) 1.48 (1.13–1.94) 
    Hypertriglyceridemia 24 31 1.47 (1.15–1.88) 1.35 (1.06–1.71) 2.04 (1.62–2.58) 1.50 (1.19–1.89) 
    Hyperglycemia 48 44 1.24 (1.02–1.50) 1.21 (0.99–1.48) 1.02 (0.84–1.22) 1.33 (1.09–1.63) 
    Metabolic syndrome       
IDF 21 28 1.49 (1.14–1.94) 1.46 (1.13–1.89) 1.94 (1.53–2.47) 1.41 (1.10–1.81) 
NCEP original 7.3 9.0 2.16 (1.34–3.49) 1.73 (1.13–2.64) 1.09 (0.77–1.55) 1.48 (1.07–2.08) 
NCEP revised 20 28 1.62 (1.22–2.14) 1.42 (1.09–1.84) 1.78 (1.39–2.27) 1.54 (1.20–1.97) 
    Hyperinsulinemia 25 33 1.66 (1.30–2.13) 1.34 (1.06–1.69) 1.52 (1.22–1.88) 1.48 (1.19–1.85) 
    High HOMA-IR 25 32 1.69 (1.31–2.18) 1.34 (1.06–1.69) 1.58 (1.27–1.96) 1.47 (1.08–1.84) 
    Low HOMA-%β 25 32 1.35 (1.07–1.70) 1.10 (0.88–1.38) 1.46 (1.18–1.81) 1.32 (1.06–1.65) 
Premenopausal women (n = 278)       
    Abdominal obesity 25 39 1.54 (1.13–2.09) 1.82 (1.29–2.56) 1.79 (1.30–2.46) 1.50 (1.06–2.14) 
    High blood pressure 34 36 1.28 (0.96–1.69) 1.12 (0.82–1.54) 1.25 (0.94–1.66) 1.33 (0.98–1.82) 
    Hypo-HDL cholesterolemia 14 1.81 (1.17–2.80) 0.99 (0.67–1.47) 1.59 (1.03–2.46) 1.35 (0.93–1.96) 
    Hypertriglyceridemia 10 14 1.99 (1.29–3.07) 1.24 (0.83–1.86) 2.50 (1.61–3.88) 1.24 (0.82–1.87) 
    Hyperglycemia 17 16 1.58 (1.13–2.21) 1.23 (0.84–1.80) 0.89 (0.62–1.28) 1.41 (0.96–2.08) 
    Metabolic syndrome       
IDF 7.9 15 2.10 (1.27–3.48) 1.28 (0.85–1.94) 2.22 (1.32–3.75) 1.63 (1.05–2.52) 
NCEP original 4.0 4.7 1.72 (0.89–3.35) 1.26 (0.65–2.45) 2.88 (1.50–5.51) 0.76 (0.39–1.45) 
NCEP revised 6.5 11 2.27 (1.26–4.09) 1.66 (1.03–2.68) 3.36 (1.78–6.32) 1.19 (0.71–1.99) 
    Hyperinsulinemia 25 30 1.70 (1.26–2.20) 1.22 (0.90–1.65) 1.62 (1.20–2.19) 1.58 (1.16–2.15) 
    High HOMA-IR 25 29 1.74 (1.28–2.35) 1.30 (0.95–1.78) 1.58 (1.17–2.15) 1.56 (1.14–2.14) 
    Low HOMA-%β 25 32 1.42 (1.05–1.93) 1.26 (0.93–1.71) 2.00 (1.47–2.73) 1.39 (1.02–1.88) 
Postmenopausal women (n = 197)       
    Abdominal obesity 46 58 1.55 (1.13–2.11) 1.12 (0.79–1.59) 1.53 (1.12–2.08) 1.15 (0.80–1.65) 
    High blood pressure 64 71 1.12 (0.82–1.53) 1.41 (0.98–2.04) 0.87 (0.64–1.19) 0.72 (0.51–1.02) 
    Hypo-HDL cholesterolemia 18 31 1.86 (1.20–2.89) 1.28 (0.87–1.88) 2.32 (1.55–3.47) 1.31 (0.89–1.94) 
    Hypertriglyceridemia 18 33 1.61 (1.04–2.49) 2.19 (1.46–3.27) 2.74 (1.79–4.20) 1.24 (0.84–1.84) 
    Hyperglycemia 24 23 1.45 (1.02–2.06) 1.43 (0.97–2.11) 1.32 (0.95–1.83) 1.32 (0.93–1.88) 
    Metabolic syndrome       
IDF 24 35 1.80 (1.21–2.68) 1.62 (1.10–2.38) 2.14 (1.47–3.10) 1.51 (1.02–2.22) 
NCEP original 8.6 12 1.74 (0.96–2.72) 1.77 (1.00–3.13) 1.37 (0.84–2.23) 1.20 (0.74–1.93) 
NCEP revised 21 34 1.88 (1.22–2.88) 1.62 (1.08–2.43) 2.10 (1.42–3.09) 1.07 (0.71–1.61) 
    Hyperinsulinemia 26 34 2.23 (1.52–3.27) 1.34 (0.93–1.92) 1.20 (0.86–1.67) 1.22 (0.87–1.71) 
    High HOMA-IR 25 32 2.16 (1.46–3.17) 1.30 (0.90–1.87) 1.19 (0.85–1.66) 1.26 (0.89–1.77) 
    Low HOMA-%β 25 34 1.37 (0.97–1.94) 1.16 (0.83–1.62) 1.04 (0.75–1.44) 1.23 (0.89–1.70) 
All individuals (n = 944)       
    Abdominal obesity 33 43 1.52 (1.30–1.77) 1.44 (1.21–1.72) 1.62 (1.39–1.88) 1.20 (1.01–1.43) 
    High blood pressure 57 60 1.19 (1.03–1.36) 1.30 (1.11–1.53) 1.06 (0.92–1.22) 1.22 (1.04–1.44) 
    Hypo-HDL cholesterolemia 13 20 1.67 (1.34–2.07) 1.17 (0.97–1.43) 1.82 (1.50–2.21) 1.42 (1.18–1.72) 
    Hypertriglyceridemia 19 26 1.60 (1.32–1.94) 1.50 (1.25–1.79) 2.24 (1.86–2.69) 1.39 (1.17–1.66) 
    Hyperglycemia 34 31 1.36 (1.17–1.58) 1.27 (1.08–1.49) 1.03 (0.89–1.19) 1.34 (1.14–1.57) 
    Metabolic syndrome       
IDF 18 26 1.70 (1.39–2.08) 1.47 (1.22–1.78) 2.01 (1.67–2.43) 1.46 (1.22–1.76) 
NCEP original 6.6 8.4 1.85 (1.37–2.51) 1.70 (1.27–2.28) 1.37 (1.07–1.77) 1.27 (1.00–1.63) 
NCEP revised 16 25 1.78 (1.43–2.20) 1.52 (1.25–1.85) 1.99 (1.63–2.42) 1.37 (1.13–1.66) 
    Hyperinsulinemia 25 32 1.78 (1.50–2.10) 1.30 (1.10–1.53) 1.46 (1.26–1.70) 1.46 (1.25–1.71) 
    High HOMA-IR 25 31 1.80 (1.52–2.14) 1.32 (1.11–1.56) 1.48 (1.27–1.73) 1.45 (1.23–1.70) 
    Low HOMA-%β 25 32 1.34 (1.14–1.57) 1.14 (0.97–1.34) 1.48 (1.27–1.73) 1.32 (1.13–1.54) 
*

Logistic model for each abnormality at entry included age, log(ferritin), and transferrin as explanatory variables; models for all individuals were adjusted for group.

Logistic model for each abnormality at the 6-year examination included age, log(ferritin), transferrin, and the corresponding abnormality at entry as explanatory variables; models for all individuals were adjusted for group.

Close Modal

or Create an Account

Close Modal
Close Modal